<DOC>
	<DOC>NCT01042795</DOC>
	<brief_summary>The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal). A 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal. The patients are followed up to 2 years.</brief_summary>
	<brief_title>Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic diagnosis of bladder carcinoma (&gt;50% urothelial carcinoma) Prior treatment with at least one cycle of platinbased neoadjuvant chemotherapy Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0 ECOG performance status of 01 (Appendix 2). No evidence of metastases within 4 weeks of registration Adequate organ and marrow function obtained within 14 days of registration Severe or uncontrolled acute or chronic medical or psychiatric condition Prior antiangiogenic therapy Prior pelvic radiation for bladder cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>bladder neoplasm</keyword>
	<keyword>adjuvant treatment</keyword>
	<keyword>disease free survival</keyword>
	<keyword>Patients with extravesical tumor (pT2-4,Nany, M0 or pTanyN+M0) after cystectomy and platin-based neoadjuvant chemotherapy</keyword>
</DOC>